Biotech Stocks

biotech stocks Are Large Cap Biotech Stocks in a Bubble?
Source: ©iStock.com/AlexRaths
Biotechnology has been one of the fastest advancing industries in the past decade. With new medicine always being synthesized and new ways to fertilize crops, the sector is diverse and prosperous, especially as corporations look for new findings or better efficiency. Subsequently, the biotech stocks are booming and should continue to rise in the future.
Some of the best biotech stocks to buy in 2014 include Amgen (NYSE:AMGN) and Gilead Sciences (NYSE:GILD) although many smaller biotech corporations are on the rise and worth a consideration. Biotech stocks can cure your ailing portfolio and lead you down the road to recovery.

Biotechnology Sector Quote (CIX: MSECTOR5151)

Recent Articles

Are Large-Cap Biotech Stocks in a Bubble?

Biotech stocks have outpaced the rest of the market by a huge margin, but it takes more than gaudy performance numbers to create a bubble. More 

MARCH MADNESS: Amgen (AMGN) vs. CVS Health (CVS)

Amgen (AMGN) and CVS Health Corp (CVS) find themselves on opposite sides when it comes to pricing for the latest drugs. More 

4 (More) Biotech Stocks to Buy

Jazz Pharmaceuticals, bluebird bio, Illumina and Celgene are the latest batch of biotech stocks worth serious consideration. More 

5 Biotech Stocks With Explosive Drug Pipelines

For many biotech stocks, drug pipelines -- not trailing results -- determine their actual value. That's good news for investors in these 5 biotechs. More 

Gilead Stock: This Beatdown Was Way Overdone (GILD)

Gilead Sciences, Inc. (GILD) was driven down by news from AbbVie, but the market may have overreacted and turned Gilead stock into a value buy. More 

2 New Funds Add a New Twist to Biotech Stocks

Calling all fans and followers of breakthrough biotech stocks! Stop searching for the next big winner and just own one of these new biotech ETFs instead. More 

3 Ways to Play the Bounce in Biotech Stocks

Biotech stocks delivered big this year for investors pursuing an aggressive growth strategy, driven by exciting new treatments for dread diseases like cancer, multiple sclerosis, hepatitis and HIV. And some have room to run in 2015. More 

Biogen: BIIB Stock Is Ready to Play Catchup

Biogen's promising results of its Alzheimer's drug sent BIIB stock rallying. Traders now have a clear line in the sand to buy the stock. More 

Trade of the Day: Gilead Sciences (GILD)

All signals point to a bullish trend, and as we dive back into the market after taking a pause, I’ve noticed that the health care sector is gaining momentum. Today, I’d like to look into a biotech position that has great growth potential. More 

Here’s What to Expect From Australian Biotechs

Australian science is strong and a leader in the biotech space. Here's why investors should look to Australia for biotech stocks to buy. More